香港股市 已收市

Bausch Health Companies Inc. (BHC)

NYSE - NYSE 延遲價格。貨幣為 USD。
加入追蹤清單
10.61+0.12 (+1.14%)
收市:04:00PM EDT
10.23 -0.38 (-3.58%)
收市後: 06:40PM EDT

Bausch Health Companies Inc.

2150 St. ElzEar Boulevard West
Laval, QC H7L 4A8
Canada
514 744 6792
https://www.bauschhealth.com

版塊Healthcare
行業Drug Manufacturers - Specialty & Generic
全職員工20,270

高階主管

名稱頭銜支付行使價出生年份
Mr. Thomas J. AppioCEO & Director4.73M1962
Ms. Seana CarsonExecutive VP & General Counsel720.5k1973
Mr. John S. BarresiSenior VP, Controller, Chief Accounting Officer & Interim CFO1973
Mr. Mirza DautbegovicSenior VP & COO
Mr. Josh CoyleSenior Vice President of Sales & Salix
Ms. Kathleen FitzpatrickSenior VP & Chief HR Officer
Dr. Tage Ramakrishna M.D.Chief Medical Officer and President of R&D1974
Mr. Jeff HartnessExecutive VP of Market Access, Commercial Operations, Neurology, Generics & Government Affairs
Dr. Graham JacksonSenior VP & Chief Quality Officer
Mr. Cees HeimanSenior Vice President of Europe & Canada
截止 2022年12月31日為止計算的金額,現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

公司管治

截至 2024年3月1日 止,Bausch Health Companies Inc. 的 ISS 管治質素評分為 4。 Pillar 分數正在審核中:5;董事會:2;股東權利:3;現金賠償:8。

企業管治評分的資料提供: Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險,而 10 分表示較高的管治風險。